The US Presidential Commission for the Study of Bioethical Issues has finished its year-long discussion of the ethical implications of applying whole genome sequencing to genetic research and clinical care, writes Dan Klotz at the commission's blog. "The Commission's recommendations," said commission chair Amy Gutmann, "clump into two big categories, one is consent to whole genome sequencing and to the possible findings and how they will be treated, and the other is oversight."